REMARKS

Claims 7, 10, 12-14, an 17-22 are withdrawn from consideration. Applicants have amended claims 1, 2, 5, 8, 9, 11, 12, 14-17, 20, 22, and 23. Applicants have also cancelled claims 6, 13, and 21 without prejudice to their later prosecution in this or another application.

Applicants acknowledge with appreciation that claims 8 and 9 would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The disclosure has been objected to because of certain informalities. Specifically, the Office has expressed concern regarding the name for formula IIA on page 16. The name has been corrected to comport with the figure. Applicants request that the objection be withdrawn.

Claims 1-6, 11, 15, 16, and 23 have been rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point and claim the invention. The Office has expressed concerns regarding the phrases "optionally substituted"; "solvate", and "cellular proliferative disease". In addition, the Office maintains that claim 6 lacks antecedent basis. Claims 1-6, 11, 15, 16, and 23 have also been rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the written description requirement.

Although Applicants respectfully maintain that the claims as presented fully comply with the requirements of § 112, Applicants have amended the claims herein to more clearly recite the presently claimed invention. Applicants respectfully request that the rejections be withdrawn.

In view of the foregoing amendments and remarks, Applicants respectfully request reconsideration and reexamination of this application and the timely allowance of the pending claims.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Bv:

Lauren L. Stevens Reg. No. 36,691